comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-02 14:03:20 - browse：67654

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Diagnostic tests are hitting their mathematical limits

hotspot

WSS

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

A public scorecard can help hold safety

UnitedHealth’s Optum accused of antitrust violations in California

Doctors find melanoma drugs effective against rare brain cancer

Organ aging and disease risk measured by new blood test

Startup Neumora takes a novel depression drug to Phase 3

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

How to save PrEP access — and even expand it

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Apple is now the first public company to be valued at $3 trillion

WHO calls for emergency meeting on new China virus, as cases spread

Drug repurposing or repositioning? The language matters

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Continuity nursing helped my family in our darkest PICU moments

Listen: Wegovy in the brain & pivotal Alzheimer's data

Drug repurposing or repositioning? The language matters

WHO calls for emergency meeting on new China virus, as cases spread

hotspot

Organ aging and disease risk measured by new blood test

Mayo Clinic plans $5B tech

How to pay for weight loss drugs and save Medicare

Startup Neumora takes a novel depression drug to Phase 3

Medicare has a new plan to address drug shortages

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

hotspot

explore

entertainment

leisure time